Clinical Trial Update: Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen [Phase 2]

View source ↗

Summary

The Phase 2 study of ABT-263 (navitoclax) in B-cell chronic lymphocytic leukemia that failed prior regimens has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• ABT-263 (navitoclax)

Snippet

Sponsor: Abbott | Conditions: B-cell Chronic Lymphocytic Leukemia | Phase 2 | Status: WITHDRAWN